Resources

Coulter Partners completed a search assignment for Tristel plc (AIM: TSTL) and is pleased to announce the placement of Anna Wasyl as Chief Financial Officer.

Dr Graham Spittle CBE has been appointed as the new Chair of Trustees at the Rosalind Franklin Institute from November 2025.

Medannex Ltd (Edinburgh) announced the presentation of the first clinical data from the ongoing Phase 1b study of MDX-124, at the European Society for Medical Oncology (ESMO) Congress 2025.

Results from a US multicenter study presented at CHEST show e-Lung could have sped up Progressive Pulmonary Fibrosis (PPF) diagnosis by up to 21 months

Cyclana Bio announced the close of a £5 million pre-seed funding round, co-led by NfX and Eka VC, and including Cocoa VC, Wilbe, and Angel investors.

A new report published today by the Cell and Gene Therapy Catapult (CGT Catapult) and the Office of Health Economics (OHE) presents a new method of quantifying the economic impact of healthcare innovations, such as cell and gene therapies.

The Oxford Science Park (TOSP), one of Europe’s leading destinations for science and technology companies, today announced the sale of part of its estate to the Ellison Institute of Technology (EIT).

Coulter Partners successfully completed a search assignment Proveca and is pleased to announce the placement of Gregory Reinaud as Chief Operating Officer (COO).

A new science specialist sixth form is set to open next year, based at Sandwich Science and Innovation Campus, Discovery Park. The new sixth form is named Carbon 6 Academy of Science, ideal for ambitious students aged 16-18 with a passion for science and maths.

Caroline founded Amici in 2005, building a company that scientists trust to power intelligent LabOps, the discipline behind efficient, compliant, and cost-effective labs. Today, Amici partners with biotech's and major pharma companies across the UK, Europe, and the US.

Precision BioSearch is delighted to have supported Maxion Therapeutics, a pioneering biotechnology company developing antibody-based drugs for ion channel and GPCR-driven diseases, with the appointment of Joel Edwards as Chief Business Officer.

Pharma multinational bets on candidates invented by GLP-1 pioneer Prof Steve Bloom to propel it into the race for next-generation obesity treatments.

VectorBuilder, a global leader in gene delivery technologies and CDMO services, today announced the publication of the miniVec plasmid system, engineered for safer, more efficient, and more scalable development of genetic medicines. The manuscript detailing this breakthrough is now available on BioRxiv.

How are pharmaceutical companies, policymakers and investors seeking growth amid fast-changing international politics, trade deals, a looming patent cliff, and technological innovation? Our maiden Life sciences and healthcare insights report offers a global perspective on disruptive forces from artificial intelligence to regulatory shifts.

Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in neurodegeneration and neuroinflammation applications.

Complement Therapeutics receives FDA IND clearance to advance its lead gene therapy CTx001 into Opti-GAIN, a Phase I/II clinical trial in Geographic Atrophy secondary to AMD

MDC will accelerate innovative life science business growth through upskilling and capability development

Every two years, Cytiva surveys 1250 biopharma executives across 22 countries and asks them to rate, on a scale of 0 to 10, the biopharma ecosystem across six pillars: supply chain resilience, talent pool, R&D ecosystem, manufacturing agility, government policy and regulation.

MORF-Bio is delighted to announce the successful closing of its pre-seed funding round to accelerate development of its microbial bioinformatics software.

Michelle Jones appointed as President and Gianni Chessari appointed as CSO.